Alzheimer's disease and its associated risk of bone fractures: a narrative review

Front Endocrinol (Lausanne). 2023 Aug 9:14:1190762. doi: 10.3389/fendo.2023.1190762. eCollection 2023.

Abstract

Background: Alzheimer's disease (AD) is a neurodegenerative disorder that is the major cause of dementia in the aged population. Recent researches indicate that patients with AD have a significantly increased fracture risk, but the pathological mechanisms are still unclear.

Objective: We systematically reviewed studies regarding bone fracture risk in AD to uncover links between the pathologies of osteoporosis and AD.

Methods: We searched the literature using the databases of PubMed, Web of Science, Embase and Cochrane Library. Studies were included if they evaluated bone fracture risk in AD patients and if they explored the pathogenesis and prevention of bone fractures in these patients.

Results: AD patients had a significantly higher risk of bone fractures than age-matched controls. Multiple factors contributed to the increased risk of bone fractures in AD patients, including the direct effects of amyloid pathology on bone cells, abnormal brain-bone interconnection, Wnt/β-catenin signalling deficits, reduced activity, high risk of falls and frailty, and chronic immune activity. Exercise, prevention of falls and fortified nutrition were beneficial for reducing the fracture risk in AD patients. However, the efficacy of anti-osteoporotic agents in preventing bone fractures should be further evaluated in AD patients as corresponding clinical studies are very scarce.

Conclusion: Alzheimer's disease patients have increased bone fracture risk and decreased bone mineral density owing to multiple factors. Assessment of anti-osteoporotic agents' efficacy in preventing bone fractures of AD patients is urgently needed.

Keywords: Alzheimer’s disease; bone fracture; pathological mechanisms; prevention; treatment.

Publication types

  • Systematic Review
  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Alzheimer Disease* / complications
  • Alzheimer Disease* / epidemiology
  • Amyloidogenic Proteins
  • Brain
  • Fractures, Bone* / epidemiology
  • Fractures, Bone* / etiology
  • Fractures, Bone* / prevention & control
  • Humans
  • Osteoporosis* / complications

Substances

  • Amyloidogenic Proteins

Grants and funding

This study is supported by National Key R&D Program of China (2018YFA0800801, 2021YFC2501704), National Natural Science Foundation of China (No.82070908), CAMS Innovation Fund for Medical Sciences (CIFMS) (2021-I2M-C&T-B-007, 2021-I2M-1-051), and National High Level Hospital Clinical Research Funding (2022-PUMCH-B-014).